Implementation of the Prostate Cancer Prevention Trial (PCPT)

The Prostate Cancer Prevention Trial is a randomized double blind chemoprevention trial of 18,882 men. It is designed to test the difference in the histologically proven prostate cancer prevalence between a group of participants given finasteride and another given placebo for 7 years. We present an...

Full description

Saved in:
Bibliographic Details
Published in:Controlled clinical trials 2004-04, Vol.25 (2), p.203-222
Main Authors: Goodman, Phyllis J, Tangen, Catherine M, Crowley, John J, Carlin, Susan M, Ryan, Anne, Coltman, Charles A, Ford, Leslie G, Thompson, Ian M
Format: Article
Language:English
Subjects:
Biological and medical sciences
Chemoprevention
Cholestenone 5 alpha-Reductase - antagonists & inhibitors
Enzyme Inhibitors - pharmacology
Finasteride
Finasteride - pharmacology
Humans
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Prevalence
Prostate cancer
Prostatic Neoplasms - enzymology
Prostatic Neoplasms - epidemiology
Prostatic Neoplasms - prevention & control
Randomized Controlled Trials as Topic - methods
Randomized Controlled Trials as Topic - statistics & numerical data
Research Design
Study management
Study organization
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The Prostate Cancer Prevention Trial is a randomized double blind chemoprevention trial of 18,882 men. It is designed to test the difference in the histologically proven prostate cancer prevalence between a group of participants given finasteride and another given placebo for 7 years. We present an overview of the study design, details of the administrative structure of the study and a description of the successful implementation of the accrual phase.
ISSN:0197-2456
1879-050X
DOI:10.1016/j.cct.2003.11.007